Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data MAXCYTE, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
21.6
26.2
33.9
44.3
41.3
38.6
33
Cost of revenue
2.5
2.77
3.65
5.1
4.74
7.1
6.22
Gross profit
19.1
23.4
30.2
39.2
36.5
31.5
26.8
Research and development
17.6
17.7
15.4
19.5
23.8
22.2
20.8
Selling and marketing
7.85
8.33
13
18.7
27
26.7
18.9
General and administrative
5.56
7.37
18.7
25.8
30.1
29.7
28.1
Operating expenses
31.5
34.5
48.4
66.5
84.8
82.7
78.7
Operating income
-12.4
-11.1
-18.2
-27.4
-48.3
-51.2
-51.9
Interest expense
0.05
0.02
0.01
Interest income
0.21
0.07
0.15
3.92
10.4
10.1
7.27
Other non-operating income
-0.48
-0.76
-0.89
3.79
10.4
10.1
7.27
Pre-tax income
-37.9
-41.1
-44.6
Income tax
0
0
0
Net income
-12.9
-11.8
-19.1
-23.6
-37.9
-41.1
-44.6
EBITDA
-11.8
-10
-16.8
-24.7
-44.1
-46.9
-47.6
EPS, basic
-0.23
-0.17
-0.21
-0.23
-0.37
-0.39
-0.42
EPS, diluted
-0.23
-0.17
-0.21
-0.23
-0.37
-0.39
-0.42
Shares, basic (weighted)
56.4
69.5
90.6
102
103
105
106
Shares, diluted (weighted)
56.4
69.5
90.6
102
103
105
106
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
15.2
18.8
47.8
11.1
46.5
27.9
20.1
Short-term investments
16
207
216
122
127
83
Receivables
5.17
6.88
11.2
5.78
4.68
3.5
Inventory
4.32
5.2
8.58
12.2
8.91
7.55
Other current assets
1
3.31
3.26
3.9
3.61
4.28
Total current assets
45.3
270
252
190
172
118
Property, plant and equipment
4.55
7.68
23.7
23.5
19.7
17.5
Lease right-of-use assets
1.73
5.69
9.85
11.2
10.8
10.9
Intangible assets
0.65
Long-term investments
42.9
35.8
52.6
Other non-current assets
0.03
0.32
0.81
0.39
1.53
2.47
Total assets
51.8
284
287
268
239
203
Accounts payable
0.89
1.82
0.29
0.74
1.36
1.4
Accrued liabilities
5.63
Deferred revenue
4.84
6.75
6.71
5.07
5.25
3.6
Total current liabilities
11.6
15.6
15.4
17.9
15.8
14.3
Long-term debt
4.92
Lease liabilities
1.23
5.15
15.9
18
17.2
16.5
Other non-current liabilities
0.79
0.45
1.32
0.28
0.27
0.26
Total liabilities
18.6
21.2
32.7
36.1
33.2
31
Paid-in capital
128
376
391
407
422
432
Retained earnings
-95.2
-114
-138
-176
-217
-261
Shareholders' equity
13.6
33.2
263
254
232
206
171
Total equity
13.6
33.2
263
254
232
206
171
Total liabilities and equity
51.8
284
287
268
239
203
Shares outstanding
77.4
101
102
104
106
107
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-12.9
-11.8
-19.1
-23.6
-37.9
-41.1
-44.6
Depreciation and amortization
0.61
1.05
1.42
2.7
4.17
4.32
4.34
Stock-based compensation
1.75
2.47
7.96
11.8
14
13.1
9.21
Change in receivables
1.59
-1.81
-1.71
-4.57
5.23
1.23
1.15
Change in inventory
-1.89
-0.89
-1.41
-3.49
-4.53
1.36
0.58
Change in payables
1.16
0.39
2.09
-0.15
3.25
-1.88
-3.72
Cash from operations
-8.8
-8.78
-10.7
-14.8
-21.7
-27.6
-34.4
Capital expenditures
-1.27
-2.07
-3.83
-18.5
-3.7
-1.65
-1.77
Acquisitions
-1.77
Purchases of investments
-7.42
-22.5
-269
-291
-255
-151
-126
Sales and maturities of investments
314
159
156
Cash from investing
0.45
-16.6
-195
-24.8
55
6.93
25.9
Stock issued
12.3
28.6
51.8
2.89
1.87
1.6
0.43
Cash from financing
12.3
28.9
235
2.89
2.14
2.06
0.66
Net change in cash
3.96
3.54
29
-36.7
35.4
-18.6
-7.82
Free cash flow
-10.1
-10.9
-14.5
-33.3
-25.4
-29.3
-36.2
Interest paid
0.67
0.42
0.42
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.17 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
79.2%
Gross profit / revenue.
Operating margin
-134.6%
Operating income / revenue.
EBITDA margin
-121.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-114.8%
Pre-tax income / revenue.
Net margin
-114.8%
Net income / revenue.
FCF margin
-76.1%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-74.0%
Cash from operations / revenue.
Return on equity (ROE)
-22.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-19.3%
Net income / average total assets.
Return on invested capital (ROIC)
-23.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
54.0%
Research and development expense / revenue.
Stock-based pay / revenue
16.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.1%
Capital expenditures / revenue.
D&A / revenue
13.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-14.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-9.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
4.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-15.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-11.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
2.8%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-16.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-12.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
38.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-15.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-10.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
31.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
8.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.3x
Current assets / current liabilities.
Quick ratio
11.1x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
10.7x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.33
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.29
Revenue / diluted weighted shares.
FCF per share
-$0.22
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.22
Cash from operations / diluted weighted shares.
Book value per share
$1.50
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
3.89x
Market cap / revenue.
P/B
0.76x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.76x
Market cap / tangible book value, when positive.
EV/Sales
0.49x
Enterprise value / revenue.
FCF yield
-19.6%
Free cash flow / market cap.
Earnings yield
-29.5%
Net income / market cap (the inverse of P/E).
What was MAXCYTE, INC.'s revenue in fiscal 2025?
MAXCYTE, INC. reported revenue of $33.0M for fiscal 2025, 14.5% lower than the year before.
Was MAXCYTE, INC. profitable in fiscal 2025?
No. It reported a net loss of $44.6M.
How much free cash flow did MAXCYTE, INC. generate in fiscal 2025?
Cash from operations of $34.4M minus capital expenditures of $1.8M left free cash flow of -$36.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.